Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ConvaTec Group Plc (CTEC.L)
Reading, GB
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.97% | +0.30% | -4.08% | -21.14% | -14.18% | -16.86% | -30.23% | -1.84% | -14.58% | -10.13% | -10.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | +1 |
| Buy | 11 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+8.8% ★ Q4'25: +16.4% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%-5.5% Q4'25: -3.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+13.9% Q4'25: +19.5% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+16.7% ★ Q4'25: +17.7% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+10.4% ★ Q4'25: +22.3% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%-1.1% ★ Q4'25: -2.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.50× Q4'25: 1.19× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 13 EPS Ana. |
Dec 2027 16 Rev. Ana. 8 EPS Ana. |
Dec 2028 14 Rev. Ana. 7 EPS Ana. |
Dec 2029 15 Rev. Ana. 6 EPS Ana. |
Dec 2030 15 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.69B
est: 1.68B (+0.3%)
|
1.76B
est: 1.73B (+1.8%)
|
1.83B
est: 1.94B (-5.5%)
|
1.83B
est: 1.76B (+3.6%)
|
1.89B
est: 1.88B (+0.9%)
|
2.04B
est: 2.03B (+0.5%)
|
2.07B
est: 2.09B (-0.9%)
|
2.14B
est: 2.78B (-23.1%)
|
2.29B
est: 2.29B (0.0%)
|
2.49B
est: 2.43B (+2.7%)
|
2.57B
2.53B – 2.61B
+6.1% YoY
|
2.75B
2.67B – 2.81B
+6.7% YoY
|
2.92B
2.85B – 2.97B
+6.3% YoY
|
3.14B
3.07B – 3.20B
+7.7% YoY
|
3.41B
3.33B – 3.47B
+8.5% YoY
|
| EBITDA |
367.70M
est: 355.62M (+3.4%)
|
451.90M
est: -202.99M (+322.6%)
|
461.50M
est: 266.14M (+73.4%)
|
424.20M
est: 356.94M (+18.8%)
|
390.70M
est: 145.65M (+168.3%)
|
405.40M
est: 150.74M (+168.9%)
|
419.10M
est: 156.19M (+168.3%)
|
455.50M
est: 617.37M (-26.2%)
|
540.20M
est: 508.76M (+6.2%)
|
644.24M
est: 537.68M (+19.8%)
|
570.28M
559.79M – 578.26M
+6.1% YoY
|
608.66M
592.33M – 623.06M
+6.7% YoY
|
646.75M
632.03M – 659.03M
+6.3% YoY
|
696.53M
680.68M – 709.75M
+7.7% YoY
|
755.97M
738.77M – 770.32M
+8.5% YoY
|
| EBIT |
203.70M
est: 209.05M (-2.6%)
|
281.10M
est: 135.84M (+106.9%)
|
280.80M
est: 263.72M (+6.5%)
|
214.40M
est: 272.40M (-21.3%)
|
224.90M
est: 98.35M (+128.7%)
|
231.30M
est: 101.79M (+127.2%)
|
245.10M
est: 105.47M (+132.4%)
|
280.10M
est: 372.55M (-24.8%)
|
319.40M
est: 307.02M (+4.0%)
|
415.54M
est: 324.47M (+28.1%)
|
344.14M
337.81M – 348.95M
+6.1% YoY
|
367.30M
357.45M – 375.99M
+6.7% YoY
|
390.28M
381.40M – 397.69M
+6.3% YoY
|
420.32M
410.76M – 428.30M
+7.7% YoY
|
456.19M
445.81M – 464.85M
+8.5% YoY
|
| Net Income |
-202.80M
est: 194.57M (-204.2%)
|
158.40M
est: -208.54M (+176.0%)
|
221.60M
est: 166.83M (+32.8%)
|
9.80M
est: 224.07M (-95.6%)
|
112.50M
est: 9.95M (+1,031.0%)
|
117.60M
est: 10.29M (+1,042.4%)
|
62.90M
est: 70.30M (-10.5%)
|
130.30M
est: 193.91M (-32.8%)
|
190.50M
est: 297.19M (-35.9%)
|
178.67M
est: 358.16M (-50.1%)
|
393.77M
380.31M – 419.31M
+9.9% YoY
|
488.03M
424.17M – 504.28M
+23.9% YoY
|
513.01M
497.83M – 525.66M
+5.1% YoY
|
575.54M
558.51M – 589.74M
+12.2% YoY
|
661.75M
642.18M – 678.09M
+15.0% YoY
|
| SGA |
669.30M
est: 638.41M (+4.8%)
|
630.50M
est: 669.32M (-5.8%)
|
647.00M
est: 648.87M (-0.3%)
|
687.40M
est: 636.92M (+7.9%)
|
714.00M
est: 681.14M (+4.8%)
|
797.90M
est: 704.95M (+13.2%)
|
790.80M
est: 730.46M (+8.3%)
|
811.30M
est: 1.03B (-21.6%)
|
840.20M
est: 852.55M (-1.4%)
|
843.33M
est: 901.01M (-6.4%)
|
955.64M
938.05M – 969.01M
+6.1% YoY
|
1.02B
992.59M – 1.04B
+6.7% YoY
|
1.08B
1.06B – 1.10B
+6.3% YoY
|
1.17B
1.14B – 1.19B
+7.7% YoY
|
1.27B
1.24B – 1.29B
+8.5% YoY
|
| EPS |
-0.10
est: 0.09 (-205.7%)
|
0.08
est: 0.15 (-47.3%)
|
0.11
est: 0.17 (-34.9%)
|
0.01
est: 0.12 (-95.9%)
|
0.06
est: 0.12 (-52.2%)
|
0.06
est: 0.13 (-54.2%)
|
0.03
est: 0.13 (-75.6%)
|
0.06
est: 0.09 (-32.6%)
|
0.09
est: 0.15 (-37.7%)
|
0.09
est: 0.18 (-50.3%)
|
0.20
0.19 – 0.21
+11.8% YoY
|
0.23
0.21 – 0.25
+14.0% YoY
|
0.25
0.24 – 0.26
+11.4% YoY
|
0.28
0.27 – 0.29
+12.2% YoY
|
0.33
0.32 – 0.33
+15.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-01 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BOSTON COMMON ASSET MANAGEMENT, LLC | 48.3K -4.8M (-99.0%) | 141.4K -15.1M (-99.1%) | 0.00% -0.235 pp | 0.01% -0.418 pp | GBp222.18 +9.5% | 12 qtrs — |
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi MSCI UK IMI SRI Climate Paris Aligned UCITS ETF DR - GBP (C) FT1K.L | 3.32% | 6.44M | 0.18% |
| 2 | Amundi MSCI UK IMI SRI Climate Paris Aligned UCITS ETF DR - EUR (C) C1U.PA | 3.32% | 6.44M | 0.18% |
| 3 | State Street SPDR S&P UK Dividend Aristocrats UCITS ETF (Dist) UKDV.L | 1.98% | 2.82M | 0.30% |
| 4 | iShares MSCI UK Small Cap UCITS ETF CUKS.L | 1.06% | 1.35M | 0.58% |
| 5 | iShares MSCI United Kingdom Small-Cap ETF EWUS | 1.06% | 426.9K | 0.59% |
| 6 | Fidelity Europe Quality Income UCITS ETF INC-EUR FEUI.L | 0.75% | 543.7K | 0.30% |
| 7 | Fidelity Europe Quality Income UCITS ETF ACC-GBP (hedged) FEQP.L | 0.75% | 637.5K | 0.35% |
| 8 | Fidelity Europe Quality Income UCITS ETF ACC-EUR FEQD.L | 0.75% | 543.7K | 0.30% |
| 9 | Fidelity Investment Trust - Fidelity Special Values PLC FSV.L | 0.46% | 8.14M | 0.27% |
| 10 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.43% | 1.48M | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan Mason | Chief Executive Officer & Director | 2M | male |
| Fiona Victoria Ryder | Group Financial Controller, Chief Financial Officer & Director | 706.8K | female |
| David Shepherd | Chief Commercial Officer | — | male |
| Divakar Ramakrishnan | Chief Science, Innovation & Quality Officer | — | — |
| Emma Rose | EVP & Chief People Officer | — | female |
| Evelyn Douglas | EVP and Chief Strategy & Business Development Officer | — | female |
| James Edward Spencer Kerton | EVP, General Counsel & Company Secretary | — | male |
| Kjersti Grimsrud Biotechnology | President & Chief Operating Officer of Infusion Care | — | female |
| Anne Belcher | President & Chief Operating Officer of Global Emerging Markets | — | female |
| Walter Morse | Interim Chief Quality & Operations Officer | — | male |
| Bruno Pinheiro | President & Chief Operating Officer of Ostomy Care | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CTEC.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
